Corneal Dystrophy
Conditions
Keywords
DMEK, DSAEK, UT-DSAEK, Endothelial cell
Brief summary
Purpose of the research is to describe and compare the evolution of BSCVA after DMEK, DSAEK and UT-DSAEK for Fuchs Endothelial Corneal Dystrophy (FECD) and Moderate Pseudophakic Bullous Keratopathy (PBK). To secondarily research the correlates criterions with best spectacle corrected visual acuity (BSCVA) 12 months postoperatively.
Detailed description
The purpose of the research is to Describe and compare the evolution of BSCVA after DMEK, DSAEK and UT-DSAEK for Fuchs Endothelial Corneal Dystrophy (FECD) and Moderate Pseudophakic Bullous Keratopathy (PBK). To secondarily research the correlates criterions with best spectacle corrected visual acuity (BSCVA) 12 months postoperatively. In a retrospective, single-center, observational study, 218 eyes treated with DMEK (n=110), UT-DSAEK (n=58) and DSAEK (n=50) surgeries were studied. Patients requiring posterior lamellar transplantation for FECD or moderate PBK, with preoperative BSCVA of less than 0.3 logmar, were selected. Patients with pathologies that may seriously affect VA postoperatively were excluded. Graft thickness for DSAEK was measured during the surgery and in vivo at D8, D15, M1, M6, M12 and M24. The primary endpoint was best spectacle corrected visual acuity (BSCVA) in logMAR at 6, 12 and 24 months. We deliberately differentiated our postoperative visual results by comparing DMEK with DSAEK or UT-DSAEK with central graft thickness (CGT) measurements carried out either pre-operatively (less than or greater than 130 µm) or post-operatively at 6 months (less than or greater than 100µm). Type of endothelial graft, Donor and recipient's ages, Graft's endothelial cell density (ECD), Rebubbling rate, preoperative VA, graft's indications and surgical time were also tested to explain BSCVA at 12 months.
Interventions
None listed
Sponsors
Centre Hospitalier Régional Metz-Thionville
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients requiring posterior lamellar transplantation for FECD or moderate PBK, with preoperative BSCVA of less than 0.3 logmar,
Exclusion criteria
* Patients with pathologies that may seriously affect VA postoperatively
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visual acuity | 6 months | The primary endpoint was best spectacle corrected visual acuity (BSCVA) in logMAR at 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Type of endothelial graft | days 1 | Type of endothelial graft |
| Donor's ages | days 1 | Donor's ages |
| recipient's ages | day 1 | recipient's ages |
| Graft's endothelial cell density | day 1 | Graft's endothelial cell density was evaluated via no-contact specular microscopy (NIDEK CEM-530 NIDEK CO. LTD). |
| central graft thickness measurements | 6 months | central graft thickness (CGT) measurements carried out either pre-operatively (less than or greater than 130 µm) or post-operatively at 6 months (less than or greater than 100µm) |
| Preoperative visual acuity | day 1 | Preoperative visual acuity was scored with reference to the logarithm of the minimum angle of resolution (LogMAR). |
| graft's indications | day 1 | The indications of the grafts are different between the DMEK groups and the DSAEK and or UT-DSAEK groups: Fuchs endothelial corneal dystrophies (FECD) and moderated pseudophakic bullous keratopathies (PBK) |
| surgical time | day 1 | surgical time |
| Rebubbling rate | day 1 | Rebubbling rate |
Countries
France
Outcome results
None listed